Gabarone Tablet
Product Images NDC 74157-111

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabarone (NDC 74157-111). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ina Pharmaceutics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (C8872d2a F3a8 4615 A89b 4a829a503eb0 01)

Chemical structure of gabapentin showing a cyclohexane ring bonded to an aminomethyl and carboxymethyl group.*

FDA Label Image

Figure 1 (C8872d2a F3a8 4615 A89b 4a829a503eb0 02)

A line graph depicting mean pain scores over an 8-week period, comparing placebo and gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, divided into 4-week dose titration and fixed dose periods. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing trend in pain scores over time, while placebo scores remain relatively constant.*

FDA Label Image

Figure 2 (C8872d2a F3a8 4615 A89b 4a829a503eb0 03)

A line graph illustrating the mean pain score over a 7-week period, comparing placebo with Gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents time in weeks, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score ranging from 0 to 10.*

FDA Label Image

Figure 3 (C8872d2a F3a8 4615 A89b 4a829a503eb0 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses across two studies. The chart shows response rates for Study 1: PBO 12% and GBP 3600 mg 29%, and Study 2: PBO 14%, GBP 1800 mg 32%, and GBP 2400 mg 34%. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (C8872d2a F3a8 4615 A89b 4a829a503eb0 05)

A scatter plot depicting difference percentages on the y-axis versus daily dose in mg on the x-axis for three studies labeled a, b, and c. Study a is shown with solid black squares, Study b with gradient gray squares, and Study c with open white squares. Data points are clustered between 600 mg and 1800 mg daily dose, with differences ranging from about 7% to 18%. The legend on the right identifies the three studies.*

FDA Label Image

100mg-90s (C8872d2a F3a8 4615 A89b 4a829a503eb0 06)

Label for GABARONE (gabapentin) tablets, 100 mg strength. The oral tablet packaging is manufactured by INA Pharmaceutics Inc. The label specifies the prescription drug status and contains storage instructions, dosage reference, and a note to dispense a Medication Guide. Package contains 90 tablets with a child-resistant container closure.*

FDA Label Image

400mg-90s (C8872d2a F3a8 4615 A89b 4a829a503eb0 07)

Label for GABARONE (gabapentin) tablets, 400 mg strength, oral dosage form, manufactured by INA Pharmaceutics Inc. The label includes dosage instructions, child-resistant packaging warning, storage temperatures, and a 90-tablet count. The label also features the NDC 74157-111-90 and a pharmacy dispensing notice for the Medication Guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.